PhaseBio Pharmaceuticals Cash ROIC

Cash ROIC of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cash ROIC growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Cash ROIC for 2020 was -411.07% (a 1330.8% increase from previous year)
  • Annual Cash ROIC for 2019 was -28.73% (a 97.19% increase from previous year)
  • Annual Cash ROIC for 2018 was -14.57% (a -64.08% decrease from previous year)
  • Twelve month Cash ROIC ending September 29, 2021 was -245.17% (a 185.95% increase compared to previous quarter)
  • Twelve month trailing Cash ROIC decreased by -30.26% year-over-year
Trailing Cash ROIC for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-245.17% -85.74% -47.24% -351.55%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cash ROIC of PhaseBio Pharmaceuticals

Most recent Cash ROICof PHAS including historical data for past 10 years.

Interactive Chart of Cash ROIC of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Cash ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -411.07%
2019 -28.73%
2018 -14.57%
2017 -40.56%
2016 -161.8%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.